Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.33 |
| ▸ | DHFR known ✓ | P00374 | 1/20 | 0.33 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305426 | 0.96 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10MYC | |
| Potassium Ion SCHEMBL3781302 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| Potassium Ion SCHEMBL11621031 | 0.86 | ALDH1A1 (0.39) | ALDH1A1KDM4EHPGDHSD17B10MYC | |
| Zinc Ion SCHEMBL28885473 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL1041780 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL143946 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL1400955 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL5964463 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| SCHEMBL28372305 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 | |
| Lithium Ion SCHEMBL756013 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669065-B1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-8053599-B2 | Drug containing (2R)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| EP-1669065-A1 | DRUG CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1669066-A1 | INFUSION PREPARATION CONTAINING (2R)-2-PROPYLOCTANOIC ACID AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105956-A1 | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | PSEN2, PRNP, GRIK5 | PTGS2 160/4885DHFR 1996/4885PTGS1 324/4885 |
| US-20070066686-A1 | Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient | PARK7, IDE, ATP6V1B2 | PTGS2 288/4885DHFR 2196/4885PTGS1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.